Cardiovascular effects of hyperthyroidism
- Irwin Klein, MD
Irwin Klein, MD
- Professor of Medicine and Endocrinology
- NYU School of Medicine
Thyroid hormone has important effects on cardiac muscle, the peripheral circulation, and the sympathetic nervous system that alter cardiovascular hemodynamics in a predictable way in patients with hyperthyroidism. The main changes are :
●Increases in heart rate, cardiac contractility, systolic and mean pulmonary artery pressure, cardiac output, diastolic relaxation, and myocardial oxygen consumption
●Reductions in systemic vascular resistance and diastolic pressure
The major cardiovascular manifestations of hyperthyroidism will be reviewed here. Other symptoms associated with this disorder are discussed separately. (See "Overview of the clinical manifestations of hyperthyroidism in adults".)
The cellular actions of thyroid hormone are mediated by the binding of triiodothyronine (T3) to nuclear receptors. It is T3 and not thyroxine (T4) that is transported into the cardiac myocyte. The subsequent binding of the T3-receptor complexes to DNA regulates the expression of genes, specifically those regulating calcium cycling in the cardiac myocyte [1,2]. T3 may also have non-nuclear actions through mechanisms not yet fully understood .To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501.
- Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 1994; 331:847.
- Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002; 12:459.
- Klein I. Endocrine disorders and cardiovascular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th, Bonow RO, Mann DL, Zipes DP, Libby P (Eds), Elsevier Saunders, Philadelphia 2017.
- Ventrella, S, Klein, I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 1994; 4:391.
- Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116:1725.
- Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991; 73:146.
- Osman F, Franklyn JA, Holder RL, et al. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 2007; 49:71.
- Iglesias P, Acosta M, Sánchez R, et al. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2005; 63:66.
- Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77:334.
- Dörr M, Wolff B, Robinson DM, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90:673.
- Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008; 5:170.
- Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58:43.
- Wustmann K, Kucera JP, Zanchi A, et al. Activation of electrical triggers of atrial fibrillation in hyperthyroidism. J Clin Endocrinol Metab 2008; 93:2104.
- Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.
- Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21:4.
- Siu CW, Yeung CY, Lau CP, et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007; 93:483.
- Ismail HM. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med 2007; 22:148.
- Schultz M, Kistorp C, Langdahl B, et al. N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. Thyroid 2007; 17:237.
- Danzi S, Klein I. Treatment of hypertension and thyroid disease. In: Advanced Therapy in Hypertension and Vascular Disease, Mohler ER, Townsend RR (Eds), BC Decker Inc., Ontario, Canada 2006. p.354.
- Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature. Cardiol Rev 2004; 12:299.
- Mercé J, Ferrás S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005; 118:126.
- Siu CW, Zhang XH, Yung C, et al. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab 2007; 92:1736.
- Peters A, Ehlers M, Blank B, et al. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 2000; 160:1993.
- Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.
- Clozel JP, Danchin N, Genton P, et al. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism. Clin Pharmacol Ther 1984; 36:64.
- Featherstone HJ, Stewart DK. Angina in thyrotoxicosis. Thyroid-related coronary artery spasm. Arch Intern Med 1983; 143:554.